Nov 12, 2021 15:31 JST
Source: Eisai
|
|
Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer's Disease (CTAD) Conference
Consistency of Efficacy Assessments Evaluated Across Various Statistical Methods
TOKYO and CAMBRIDGE, Mass., Nov 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today results of sensitivity analyses evaluating the consistency of lecanemab efficacy results across multiple statistical models in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD). This presentation was made by Eisai at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) conference, November 9-12, 2021 in Boston, Massachusetts and virtually. In September 2021, Eisai initiated a rolling submission of a Biologics License Application (BLA) for lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of early AD, to the U.S. Food and Drug Administration (FDA) under the accelerated approval pathway. Study 201, a multicenter, double-blind, placebo-controlled, Phase 2b trial conducted in 856 patients with early AD, evaluated key efficacy assessments, including clinical change on the Alzheimer's Disease Composite Score (ADCOMS) at the primary endpoint of 12 months and at select key secondary endpoints, Clinical Dementia Rating-Sum-of-Boxes (CDR-SB) and Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) at 18 months. Six sensitivity analyses across four statistical models (mixed model for repeated measures, disease progression model, natural cubic spline model, and quadratic mixed model) showed consistent positive lecanemab treatment effects for ADCOMS, CDR-SB and ADAS-Cog14 at 18 months. The primary endpoint was Bayesian analysis of 12-month clinical change on ADCOMS with the goal to identify the most efficacious dose (ED90 dose). Primary analysis was super-superiority over placebo by ≥25%: goal was 80% probability of >/=25% reduction in decline versus placebo. Study achieved the goal of identifying smallest dose that achieved ≥90% of maximum treatment effect (10 mg/kg biweekly), i.e., the ED90 dose. At 12 months, ED90 dose had 64% probability of being super-superior to placebo by 25% reduction. At 12 months, ED90 dose had 98% probability superior to placebo. Consistent treatment effect was observed at 18 months for ADCOMS (29% to 37%), CDR-SB (26.5% to 35%), and ADAS-Cog (47% to 56%), with separation from placebo observed by six months for the top dose (10mg/kg biweekly) across all analyses. "In Study 201, lecanemab showed robust clearance of brain amyloid and slowing of clinical decline across several clinical and biomarker endpoints. This sensitivity analysis shows lecanemab clinical efficacy results across statistical models are consistent, reliable and further enhances our confidence in the clinical potential of this investigational therapy," said Michael Irizarry, M.D., Vice President, Deputy Chief Clinical Officer, Neurology Business Group, Eisai Inc. "Through our comprehensive research program, we will continue to advance the understanding of how this anti-amyloid beta protofibril antibody may play a role in the treatment of early and preclinical AD. In March 2021, Eisai completed enrollment of 1,795 patients with early Alzheimer's disease in our confirmatory Phase 3 Clarity AD clinical study. The Phase 3 clinical study, AHEAD 3-45, is currently exploring lecanemab's safety and efficacy in individuals with preclinical AD." This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agent will successfully complete clinical development or gain health authority approval.
For more information, visit https://www.eisai.com/news/2021/news202187.html.
Source: Eisai Sectors: BioTech
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
|
Latest Release
Mitsubishi Shipbuilding Receives Order from the University of Tokyo for "MiPoLin" Power Prediction and Lines Selection System Mar 28, 2024 16:45 JST
| Mitsubishi Logisnext Completes Demonstration of Automated Truck Loading, Leading to Start of Actual Operations in Japan Mar 28, 2024 13:52 JST
| Toyota Releases Sales, Production, and Export Results for February 2024 Mar 28, 2024 13:35 JST
| TANAKA to Install 500 kW Fuel Cell System to Promote the Use of Hydrogen Energy at Production Plants Mar 28, 2024 03:00 JST
| PEVE to change name to TOYOTA BATTERY Co., Ltd. and produce batteries for a wide range of electric vehicles Mar 27, 2024 15:13 JST
| NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy System Mar 27, 2024 15:00 JST
| TANAKA Holdings Announces Green Loan Financing for Construction of New Head Office Building Mar 27, 2024 03:00 JST
| JFE Steel and Hitachi Jointly Started Providing Solutions for the Steel Industry Mar 26, 2024 19:04 JST
| La Banque Postale and JCB join forces to elevate payments experience for travellers in France Mar 26, 2024 15:00 JST
| Fujitsu Tech Leverages AI and Underwater Drone Data for 'Ocean Digital Twin' Mar 26, 2024 10:24 JST
| NEC develops marketing strategy planning & effectiveness simulation technology using generative AI Mar 25, 2024 10:08 JST
| Toyota to Open New Tokyo Head Office in Shinagawa in FY2030 Mar 22, 2024 16:15 JST
| Hitachi Selected as CDP Supplier Engagement Leader for the Third Consecutive Year Mar 22, 2024 16:04 JST
| Mitsubishi Motors Celebrates Production of 100,000th fully electric minivehicle Mar 22, 2024 15:34 JST
| JCB and AEON Credit Service Indonesia Launch the AEON JCB Precious Card Mar 22, 2024 15:00 JST
| JCB Issues White Paper on Calculating CO2 Emissions by Payment Method in Japan Mar 22, 2024 12:00 JST
| NEC and NTT successfully conduct first-of-its-kind long-distance transmission experiment over 7,000km using 12-core optical fiber Mar 22, 2024 08:38 JST
| Lifenet and Eisai Co-Develop Dementia Insurance "be" Mar 21, 2024 17:36 JST
| Toyota: Clarification of the Roles of and Expectations for Outside Executives, Revision of the Independence Assessment Criteria, and the Changes to Members of the Board of Directors and the Audit and Supervisory Board Members following the 120th Ordinary General Shareholders' Meeting Mar 21, 2024 16:47 JST
| Sales of Evolved GR Yaris to Start in April, While Purchasing Lotteries for WRC Driver-supervised Special Editions Start Today Mar 21, 2024 16:31 JST
|
More Latest Release >>
|